Pfizer (PFE) has released the results from its Phase 3 clinical trial for its RSV vaccine. The trial showed positive outcomes for adults aged 18-59, widening the population that can potentially benefit from the vaccine. Previously, Pfizer's RSV vaccine had been approved for use in pregnant women and adults aged 60 and older. Yahoo Finance's Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. Editor's note: This article was written by Angel Smith
Pfizer (PFE) has released the results from its Phase 3 clinical trial for its RSV vaccine. The trial showed positive outcomes for adults aged 18-59, widening the population that can potentially benefit from the vaccine. Previously, Pfizer's RSV vaccine had been approved for use in pregnant women and adults aged 60 and older.
Yahoo Finance's Health Reporter Anjalee Khemlani breaks down the details.
For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime.
Editor's note: This article was written by Angel Smith
Bloomberg
(Bloomberg) -- A block trade in US short-term interest-rate futures Tuesday was the biggest on record and helped drive gains for the Treasury market.Most Read from BloombergTrumpism Is Emptying ChurchesIran’s Better, Stealthier Drones Are Remaking Global WarfareUkraine Says It’s Behind Blaze on Russian Warship in Baltic SeaBillionaire Geiger, Blackstone Near L’Occitane DealS&P 500 Stages Late-Day Rebound With CPI in Focus: Markets WrapThe trade involved futures on the Secured Overnight Financing
Reuters
The vaccine, designed to train the immune system of patients to recognize and attack specific mutations in cancer cells, earlier showed promise in treating melanoma in a mid-stage study. "The data continue to validate the individualized therapy platform and suggests it could potentially work in indications outside melanoma," Jefferies analyst Michael Yee said in a note. Yee said the combination showed a strong benefit in extending survival, versus a previous trial testing Keytruda alone.
Read more --->